Email
Print
Overactive Bladder Treatment Market - Forecast(2024 - 2030)
Overview
Overactive bladder treatment market size in 2018, is $3.7 billion and is projected to reach revenue of $4.61 billion by 2025. Overactive bladder is the condition in which there is an uncontrollable need to urinate. OAB treatments include lifestyle changes, medications, Botox treatments, nerve simulation, and even surgery.
Key Takeaways
- The market is estimated to grow at a CAGR of 3.1% during the forecast period 2019-2025 owing to the rising prevalence of urinary incontinence among women and geriatric population. FDA drug approvals are increasing especially for generic drugs and this tends to drive the market.
- Companies are adopting various strategic alliances to expand
in various regions. They are also developing new technology to reduce the
symptoms and treat overactive bladder.
Pharmacotherapy - Segment Analysis
Initial treatments for urge
incontinence include pelvic floor exercises, bladder training and behavioral
methods. Anticholinergic treatments block the neurotransmission thus reducing
the feeling of urgency. This segment is said to occupy major share but its
demand is decreasing as these drugs cause many side effects. Botox or Botulinum
toxin helps strengthen the bladder. Its dose ranges from 50-300 units and has
to be injected repeatedly as the toxin dose wears off. The Botox segment is
said to have the fastest growth rate with CAGR 2.9% and there has been an increase
in use of Botox among patients who do not prefer surgery or oral medication.
Disease - Segment Analysis
Idiopathic overactive
bladder is to account for the major share among diseases that cause OAB. This
is owing to the rise in OAB among women post menopause or pregnancy as well as
among the geriatric population. Urinary tract infections are also known to
cause OAB as this condition increases activation of the bladder muscles. Diseases
such as diabetes insipidus results in excessive urination which is often
misunderstood as OAB. And such similar symptoms result in oversight of the major
disease.
Geography - Segment Analysis
North America accounts for
largest Overactive bladder treatment market share with 48% in 2018. This is
owing to the high prevalence of this disease among Americans. As per the National
Association for Continence, OAB affects an estimated 33 million people in the
USA alone. Thus the treatment demand for this is likely to be high. However,
Asia Pacific is expected to have the fastest growth as the prevalence of OAB is
rising and also due to the increasing awareness on OAB among the people.
Drivers – Overactive Bladder Treatment Market
·
Increase in Aging Population
and rising OAB occurrence among women
Urinary or urge incontinence
is the condition that results from delay in treatment of an overactive bladder.
This is prevalent among women and older population. As per WHO - Integrated
care for older people (2017), the prevalence of urinary incontinence is twice
as high in older women as in older men. Thus a rise in the geriatric population
coupled by diseases that are resultant from OAB are contributing to growth of OAB
treatment market.
·
Increasing Drug Developments
for Overactive Bladder Treatment
Many drugs are being developed
for Overactive bladder treatment by various companies. They are focusing on
combination therapies and drugs with minimal side effects. Drug approvals are
also increasing due to the rising prevalence of overactive bladder. FDA is also
increasing approvals on generic drugs thus also lowering the prices. This is
because of new regulatory authorities by FDA to speed up drug approvals. This
encourages competition and more companies come out with drugs.
Challenges – Overactive Bladder Treatment Market
· Side Effects of Current Treatments
Anticholinergic drugs used for
treatment of OAB have harmful side effects. These drugs interact with the brain
or neural system and can result in memory loss, hallucinations, insomnia and
other effects. Even Botox treatment have side effects like urinary tract
infections. The side effects by these treatments tend to challenge the growth
of the market.
Overactive Bladder Treatment Industry Outlook
Research & development along
with strategic alliances are some of the key strategies adopted by players in
the Overactive Bladder Treatment market. Overactive Bladder Treatment Market
top 10 companies are Astellas Pharma Inc, Pfizer, Inc, Teva Pharmaceutical
Industries Limited, Allergan, PLC, Mylan N.V, Hisamitsu Pharmaceutical Co.,
Inc, Sanofi, Aurobindo Pharma Limited, Johnson & Johnson, and Medtronic
PLC.
The company, Triple W
developed DFree, a wearable device for incontinence that can track the
progression of bladder movements using a non-invasive ultrasonic sensor.
Overactive Bladder Treatment Market Research Scope:
The base year of the study
is 2018, with forecast done up to 2025. The study presents a thorough analysis
of the competitive landscape, taking into account the market shares of the
leading companies. These provide the key market participants with the necessary
business intelligence and help them understand the future of the Overactive
Bladder Treatment Market. The assessment includes the forecast, an overview of
the competitive structure, the market shares of the competitors, as well as the
market trends, market demands, market drivers, market challenges, and product
analysis. The market drivers and restraints have been assessed to fathom their
impact over the forecast period. This report further identifies the key
opportunities for growth while also detailing the key challenges and possible
threats.
For more Lifesciences and Healthcare related reports, please click here
1.1 Definitions and Scope
2. Overactive Bladder Treatment Market - Executive summary
2.1 Market Revenue, Market Size and Key Trends by Company
2.2 Key Trends by type of Application
2.3 Key Trends segmented by Geography
3. Overactive Bladder Treatment Market
3.1 Comparative analysis
3.1.1 Product Benchmarking - Top 10 companies
3.1.2 Top 5 Financials Analysis
3.1.3 Market Value split by Top 10 companies
3.1.4 Patent Analysis - Top 10 companies
3.1.5 Pricing Analysis
4. Overactive Bladder Treatment Market - Startup companies Scenario Premium
4.1 Top 10 startup company Analysis by
4.1.1 Investment
4.1.2 Revenue
4.1.3 Market Shares
4.1.4 Market Size and Application Analysis
4.1.5 Venture Capital and Funding Scenario
5. Overactive Bladder Treatment Market - Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing business index
5.3 Case studies of successful ventures
5.4 Customer Analysis - Top 10 companies
6. Overactive Bladder Treatment Market Forces
6.1 Drivers
6.2 Constraints
6.3 Challenges
6.4 Porters five force model
6.4.1 Bargaining power of suppliers
6.4.2 Bargaining powers of customers
6.4.3 Threat of new entrants
6.4.4 Rivalry among existing players
6.4.5 Threat of substitutes
7. Overactive Bladder Treatment Market -Strategic analysis
7.1 Value chain analysis
7.2 Opportunities analysis
7.3 Product life cycle
7.4 Suppliers and distributors Market Share
8. Overactive Bladder Treatment Market - By Pharmacotherapy (Market Size -$Million / $Billion)
8.1 Introduction
8.2 Anticholinergics
8.2.1 Solifenacin
8.2.2 Oxybutynin
8.2.3 Fesoterodine
8.2.4 Darifenacin
8.2.5 Tolterodine
8.2.6 Trospium
8.2.7 Other Anticholinergics
8.3 Mirabegron
8.4 Botox
8.5 Neurostimulation
8.6 Intravesical Instillation
9. Overactive Bladder Treatment Market - By Disease (Market Size -$Million / $Billion)
9.1 Introduction
9.2 Idiopathic Overactive Bladder
9.3 Neurogenic Overactive Bladder
9.3.1 Introduction
9.3.2 Overactive Bladder in Parkinson's Disease
9.3.3 Overactive Bladder in Stroke
9.3.4 Overactive Bladder in Multiple Sclerosis
9.3.5 Overactive Bladder in Spinal Cord Injury
9.3.6 Overactive Bladder in Other Disorders
10. Overactive Bladder Treatment - By Application Type (Market Size -$Million / $Billion)
10.1 Segment type Size and Market Share Analysis
10.2 Application Revenue and Trends by type of Application
10.3 Application Segment Analysis by Type
11. Overactive Bladder Treatment- By Geography (Market Size -$Million / $Billion)
11.1 Overactive Bladder Treatment Market - North America Segment Research
11.2 North America Market Research (Million / $Billion)
11.2.1 Segment type Size and Market Size Analysis
11.2.2 Revenue and Trends
11.2.3 Application Revenue and Trends by type of Application
11.2.4 Company Revenue and Product Analysis
11.2.5 North America Product type and Application Market Size
11.2.5.1 U.S
11.2.5.2 Canada
11.2.5.3 Mexico
11.2.5.4 Rest of North America
11.3 Overactive Bladder Treatment- South America Segment Research
11.4 South America Market Research (Market Size -$Million / $Billion)
11.4.1 Segment type Size and Market Size Analysis
11.4.2 Revenue and Trends
11.4.3 Application Revenue and Trends by type of Application
11.4.4 Company Revenue and Product Analysis
11.4.5 South America Product type and Application Market Size
11.4.5.1 Brazil
11.4.5.2 Venezuela
11.4.5.3 Argentina
11.4.5.4 Ecuador
11.4.5.5 Peru
11.4.5.6 Colombia
11.4.5.7 Costa Rica
11.4.5.8 Rest of South America
11.5 Overactive Bladder Treatment- Europe Segment Research
11.6 Europe Market Research (Market Size -$Million / $Billion)
11.6.1 Segment type Size and Market Size Analysis
11.6.2 Revenue and Trends
11.6.3 Application Revenue and Trends by type of Application
11.6.4 Company Revenue and Product Analysis
11.6.5 Europe Segment Product type and Application Market Size
11.6.5.1 U.K
11.6.5.2 Germany
11.6.5.3 Italy
11.6.5.4 France
11.6.5.5 Netherlands
11.6.5.6 Belgium
11.6.5.7 Denmark
11.6.5.8 Spain
11.6.5.9 Rest of Europe
11.7 Overactive Bladder Treatment - APAC Segment Research
11.8 APAC Market Research (Market Size -$Million / $Billion)
11.8.1 Segment type Size and Market Size Analysis
11.8.2 Revenue and Trends
11.8.3 Application Revenue and Trends by type of Application
11.8.4 Company Revenue and Product Analysis
11.8.5 APAC Segment - Product type and Application Market Size
11.8.5.1 China
11.8.5.2 Australia
11.8.5.3 Japan
11.8.5.4 South Korea
11.8.5.5 India
11.8.5.6 Taiwan
11.8.5.7 Malaysia
11.8.5.8 Hong kong
11.8.5.9 Rest of APAC
11.9 Overactive Bladder Treatment - Middle East Segment and Africa Segment Research
11.10 Middle East & Africa Market Research (Market Size -$Million / $Billion)
11.10.1 Segment type Size and Market Size Analysis
11.10.2 Revenue and Trend Analysis
11.10.3 Application Revenue and Trends by type of Application
11.10.4 Company Revenue and Product Analysis
11.10.5 Middle East Segment Product type and Application Market Size
11.10.5.1 Israel
11.10.5.2 Saudi Arabia
11.10.5.3 UAE
11.10.6 Africa Segment Analysis
11.10.6.1 South Africa
11.10.6.2 Rest of Middle East & Africa
12. Overactive Bladder Treatment Market - Entropy
12.1 New product launches
12.2 M&A s, collaborations, JVs and partnerships
13. Overactive Bladder Treatment Market - Industry / Segment Competition landscape Premium
13.1 Market Share Analysis
13.1.1 Market Share by Country- Top companies
13.1.2 Market Share by Region- Top 10 companies
13.1.3 Market Share by type of Application - Top 10 companies
13.1.4 Market Share by type of Product / Product category- Top 10 companies
13.1.5 Market Share at global level - Top 10 companies
13.1.6 Best Practises for companies
14. Overactive Bladder Treatment Market - Key Company List by Country Premium
15. Overactive Bladder Treatment Market Company Analysis
15.1 Market Share, Company Revenue, Products, M&A, Developments
15.2 Allergan, Plc
15.3 Apotex Inc
15.4 Astellas Pharma Inc
15.5 Aurobindo Pharma Limited
15.6 Cogentix Medical, Inc
15.7 Endo International Plc
15.8 Hisamitsu Pharmaceutical Co , Inc
15.9 Intas Pharmaceutical Ltd
15.10 Johnson & Johnson
15.11 Macleod Pharmaceutical Ltd
15.12 Medtronic Plc
15.13 Mylan N V
15.14 Pfizer, Inc
15.15 Sanofi
15.16 Teva Pharmaceutical Industry Limited
15.17 Company 16
15.18 Company 17 & More
16.1 Abbreviations
16.2 Sources
17. Overactive Bladder Treatment Market - Methodology
17.1 Research Methodology
17.1.1 Company Expert Interviews
17.1.2 Industry Databases
17.1.3 Associations
17.1.4 Company News
17.1.5 Company Annual Reports
17.1.6 Application Trends
17.1.7 New Products and Product database
17.1.8 Company Transcripts
17.1.9 R&D Trends
17.1.10 Key Opinion Leaders Interviews
17.1.11 Supply and Demand Trends
LIST OF TABLES
1.Global Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 ($M)1.1 Anticholinergic Market 2023-2030 ($M) - Global Industry Research
1.1.1 Solifenacin Market 2023-2030 ($M)
1.1.2 Oxybutynin Market 2023-2030 ($M)
1.1.3 Fesoterodine Market 2023-2030 ($M)
1.1.4 Darifenacin Market 2023-2030 ($M)
1.1.5 Tolterodine Market 2023-2030 ($M)
1.1.6 Trospium Market 2023-2030 ($M)
1.2 Mirabegron Market 2023-2030 ($M) - Global Industry Research
1.3 Botox Market 2023-2030 ($M) - Global Industry Research
1.4 Neurostimulation Market 2023-2030 ($M) - Global Industry Research
1.5 Intravesical Instillation Market 2023-2030 ($M) - Global Industry Research
2.Global Overactive Bladder Treatment Market, By Disease Market 2023-2030 ($M)
2.1 Idiopathic Overactive Bladder Market 2023-2030 ($M) - Global Industry Research
2.2 Neurogenic Overactive Bladder Market 2023-2030 ($M) - Global Industry Research
2.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 ($M)
2.2.2 Overactive Bladder In Stroke Market 2023-2030 ($M)
2.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 ($M)
2.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 ($M)
3.Global Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 (Volume/Units)
3.1 Anticholinergic Market 2023-2030 (Volume/Units) - Global Industry Research
3.1.1 Solifenacin Market 2023-2030 (Volume/Units)
3.1.2 Oxybutynin Market 2023-2030 (Volume/Units)
3.1.3 Fesoterodine Market 2023-2030 (Volume/Units)
3.1.4 Darifenacin Market 2023-2030 (Volume/Units)
3.1.5 Tolterodine Market 2023-2030 (Volume/Units)
3.1.6 Trospium Market 2023-2030 (Volume/Units)
3.2 Mirabegron Market 2023-2030 (Volume/Units) - Global Industry Research
3.3 Botox Market 2023-2030 (Volume/Units) - Global Industry Research
3.4 Neurostimulation Market 2023-2030 (Volume/Units) - Global Industry Research
3.5 Intravesical Instillation Market 2023-2030 (Volume/Units) - Global Industry Research
4.Global Overactive Bladder Treatment Market, By Disease Market 2023-2030 (Volume/Units)
4.1 Idiopathic Overactive Bladder Market 2023-2030 (Volume/Units) - Global Industry Research
4.2 Neurogenic Overactive Bladder Market 2023-2030 (Volume/Units) - Global Industry Research
4.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 (Volume/Units)
4.2.2 Overactive Bladder In Stroke Market 2023-2030 (Volume/Units)
4.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 (Volume/Units)
4.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 (Volume/Units)
5.North America Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 ($M)
5.1 Anticholinergic Market 2023-2030 ($M) - Regional Industry Research
5.1.1 Solifenacin Market 2023-2030 ($M)
5.1.2 Oxybutynin Market 2023-2030 ($M)
5.1.3 Fesoterodine Market 2023-2030 ($M)
5.1.4 Darifenacin Market 2023-2030 ($M)
5.1.5 Tolterodine Market 2023-2030 ($M)
5.1.6 Trospium Market 2023-2030 ($M)
5.2 Mirabegron Market 2023-2030 ($M) - Regional Industry Research
5.3 Botox Market 2023-2030 ($M) - Regional Industry Research
5.4 Neurostimulation Market 2023-2030 ($M) - Regional Industry Research
5.5 Intravesical Instillation Market 2023-2030 ($M) - Regional Industry Research
6.North America Overactive Bladder Treatment Market, By Disease Market 2023-2030 ($M)
6.1 Idiopathic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
6.2 Neurogenic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
6.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 ($M)
6.2.2 Overactive Bladder In Stroke Market 2023-2030 ($M)
6.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 ($M)
6.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 ($M)
7.South America Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 ($M)
7.1 Anticholinergic Market 2023-2030 ($M) - Regional Industry Research
7.1.1 Solifenacin Market 2023-2030 ($M)
7.1.2 Oxybutynin Market 2023-2030 ($M)
7.1.3 Fesoterodine Market 2023-2030 ($M)
7.1.4 Darifenacin Market 2023-2030 ($M)
7.1.5 Tolterodine Market 2023-2030 ($M)
7.1.6 Trospium Market 2023-2030 ($M)
7.2 Mirabegron Market 2023-2030 ($M) - Regional Industry Research
7.3 Botox Market 2023-2030 ($M) - Regional Industry Research
7.4 Neurostimulation Market 2023-2030 ($M) - Regional Industry Research
7.5 Intravesical Instillation Market 2023-2030 ($M) - Regional Industry Research
8.South America Overactive Bladder Treatment Market, By Disease Market 2023-2030 ($M)
8.1 Idiopathic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
8.2 Neurogenic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
8.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 ($M)
8.2.2 Overactive Bladder In Stroke Market 2023-2030 ($M)
8.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 ($M)
8.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 ($M)
9.Europe Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 ($M)
9.1 Anticholinergic Market 2023-2030 ($M) - Regional Industry Research
9.1.1 Solifenacin Market 2023-2030 ($M)
9.1.2 Oxybutynin Market 2023-2030 ($M)
9.1.3 Fesoterodine Market 2023-2030 ($M)
9.1.4 Darifenacin Market 2023-2030 ($M)
9.1.5 Tolterodine Market 2023-2030 ($M)
9.1.6 Trospium Market 2023-2030 ($M)
9.2 Mirabegron Market 2023-2030 ($M) - Regional Industry Research
9.3 Botox Market 2023-2030 ($M) - Regional Industry Research
9.4 Neurostimulation Market 2023-2030 ($M) - Regional Industry Research
9.5 Intravesical Instillation Market 2023-2030 ($M) - Regional Industry Research
10.Europe Overactive Bladder Treatment Market, By Disease Market 2023-2030 ($M)
10.1 Idiopathic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
10.2 Neurogenic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
10.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 ($M)
10.2.2 Overactive Bladder In Stroke Market 2023-2030 ($M)
10.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 ($M)
10.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 ($M)
11.APAC Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 ($M)
11.1 Anticholinergic Market 2023-2030 ($M) - Regional Industry Research
11.1.1 Solifenacin Market 2023-2030 ($M)
11.1.2 Oxybutynin Market 2023-2030 ($M)
11.1.3 Fesoterodine Market 2023-2030 ($M)
11.1.4 Darifenacin Market 2023-2030 ($M)
11.1.5 Tolterodine Market 2023-2030 ($M)
11.1.6 Trospium Market 2023-2030 ($M)
11.2 Mirabegron Market 2023-2030 ($M) - Regional Industry Research
11.3 Botox Market 2023-2030 ($M) - Regional Industry Research
11.4 Neurostimulation Market 2023-2030 ($M) - Regional Industry Research
11.5 Intravesical Instillation Market 2023-2030 ($M) - Regional Industry Research
12.APAC Overactive Bladder Treatment Market, By Disease Market 2023-2030 ($M)
12.1 Idiopathic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
12.2 Neurogenic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
12.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 ($M)
12.2.2 Overactive Bladder In Stroke Market 2023-2030 ($M)
12.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 ($M)
12.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 ($M)
13.MENA Overactive Bladder Treatment Market, By Pharmacotherapy Market 2023-2030 ($M)
13.1 Anticholinergic Market 2023-2030 ($M) - Regional Industry Research
13.1.1 Solifenacin Market 2023-2030 ($M)
13.1.2 Oxybutynin Market 2023-2030 ($M)
13.1.3 Fesoterodine Market 2023-2030 ($M)
13.1.4 Darifenacin Market 2023-2030 ($M)
13.1.5 Tolterodine Market 2023-2030 ($M)
13.1.6 Trospium Market 2023-2030 ($M)
13.2 Mirabegron Market 2023-2030 ($M) - Regional Industry Research
13.3 Botox Market 2023-2030 ($M) - Regional Industry Research
13.4 Neurostimulation Market 2023-2030 ($M) - Regional Industry Research
13.5 Intravesical Instillation Market 2023-2030 ($M) - Regional Industry Research
14.MENA Overactive Bladder Treatment Market, By Disease Market 2023-2030 ($M)
14.1 Idiopathic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
14.2 Neurogenic Overactive Bladder Market 2023-2030 ($M) - Regional Industry Research
14.2.1 Overactive Bladder In Parkinson'S Disease Market 2023-2030 ($M)
14.2.2 Overactive Bladder In Stroke Market 2023-2030 ($M)
14.2.3 Overactive Bladder In Multiple Sclerosis Market 2023-2030 ($M)
14.2.4 Overactive Bladder In Spinal Cord Injury Market 2023-2030 ($M)
LIST OF FIGURES
1.US Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)2.Canada Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
3.Mexico Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
4.Brazil Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
5.Argentina Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
6.Peru Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
7.Colombia Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
8.Chile Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
9.Rest of South America Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
10.UK Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
11.Germany Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
12.France Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
13.Italy Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
14.Spain Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
15.Rest of Europe Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
16.China Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
17.India Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
18.Japan Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
19.South Korea Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
20.South Africa Overactive Bladder Treatment Market Revenue, 2023-2030 ($M)
21.North America Overactive Bladder Treatment By Application
22.South America Overactive Bladder Treatment By Application
23.Europe Overactive Bladder Treatment By Application
24.APAC Overactive Bladder Treatment By Application
25.MENA Overactive Bladder Treatment By Application
26.Astellas Pharma Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Pfizer, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
28.Teva Pharmaceutical Industry Limited, Sales /Revenue, 2015-2018 ($Mn/$Bn)
29.Allergan, Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
30.Mylan N V, Sales /Revenue, 2015-2018 ($Mn/$Bn)
31.Endo International Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
32.Hisamitsu Pharmaceutical Co , Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
33.Sanofi, Sales /Revenue, 2015-2018 ($Mn/$Bn)
34.Aurobindo Pharma Limited, Sales /Revenue, 2015-2018 ($Mn/$Bn)
35.Johnson & Johnson, Sales /Revenue, 2015-2018 ($Mn/$Bn)
36.Intas Pharmaceutical Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
37.Apotex Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
38.Macleod Pharmaceutical Ltd, Sales /Revenue, 2015-2018 ($Mn/$Bn)
39.Medtronic Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)
40.Cogentix Medical, Inc, Sales /Revenue, 2015-2018 ($Mn/$Bn)